Navigation Links
Common infant virus may trigger type 1 diabetes
Date:12/18/2008

Human parechovirus is a harmless virus which is encountered by most infants and displays few symptoms. Suspected of triggering type 1 diabetes in susceptible people, research methods need to take this "silent" virus into consideration. This comes from findings in a study from the Norwegian Institute of Public Health.

This study was part of a long-term project at the Norwegian Institute of Public Health to investigate if environmental risk factors affect type 1 diabetes. Faecal samples and questionnaires about the health of 102 children were sent in monthly by their parents for closer study.

Researchers wanted to see how common human parechovirus infections were among Norwegian infants. Existing research indicates that a related virus which only affects rodents, Ljungan virus, has been linked to the development of rodent diabetes.

Common virus

By studying stool samples from 102 infants and comparing feedback from parents about their child's health over three years, no significant link could be found between infection episodes and typical symptoms such as coughing, sneezing, vomiting, diarrhoea or fever. By the age of two, 86 percent of the infants had evidence of parechovirus in their faeces, and 94 percent by the age of three. Human parechovirus 1 was the most prevalent type (76 percent) followed by human parechoviruses 3 and 6 (13 percent and 9 percent respectively).

The researchers also noticed an increase in parechovirus infection between the ages of 6 and 18 months. This could be due to the loss of maternal antibodies by 6 months of age or the exposure to nursery/play groups that often begins at this age in Norway. Most infections occurred during September to December.

The 102 infants were recruited from babies born in 2004, with half from the high risk group for diabetes type 1 and the rest from a low risk group. The "high-risk" group included babies who had been identified at birth to carry the HLA genotype conferring the highest known risk for type 1 diabetes. The group not carrying the high-risk genotype included babies born at the same time and in the same area to the high risk babies.

The researchers conclude that most infants are infected by human parechovirus without displaying symptoms and so the total number of previous infections should be considered when looking for triggers for type 1 diabetes among those who are genetically at risk. Perhaps too few infections or infection at a too late time point could be important.


'/>"/>

Contact: Media Contact
julie.johansen@fhi.no
Norwegian Institute of Public Health
Source:Eurekalert

Related medicine news :

1. UK junior doctors gaining less experience of common procedures
2. New insights into common knee injuries
3. High and mighty: first common height gene identified by researchers behind obesity gene finding
4. Figure Skater Peggy Fleming, HealthSaver Says: Take Pains For Back Strains, 2nd Most Common Doctor Complaint
5. Exelixis Commences Public Offering of Common Stock
6. Common misdiagnosis: most women believe they have a yeast infection when they dont
7. Business Executives Discuss National Health Care Reform at Conference Sponsored by The Century Foundation, with Support from The Commonwealth Fund, and AARP
8. New Expert Report Dispels Common Myths About Aspartame
9. Common Foot Myths Trip Us Up
10. AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange
11. Allergy-Induced Asthma More Common in Affluent Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... ... Bellus Medical, a leader in medical aesthetics, recently acquired ... photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically formulated to ... minimize the appearance of pores – all with minimal downtime and results that ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges ... for how his administration could impact the employee benefits industry. James Slotnick, AVP, ... most likely to make it through Congress. His discussion will focus on the ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies ... to help with process innovation in drug formulation and manufacturing. CoreRx offers ... state-of-the-art analytical equipment in support of their development and manufacturing goals. , ...
(Date:4/25/2017)... CA (PRWEB) , ... April 25, 2017 , ... ... the addition of predictive analytics to its patient care management module. Using this ... even before a patient has been initiated on continuous positive airway pressure (CPAP), ...
(Date:4/24/2017)... Massachusetts (PRWEB) , ... April 24, 2017 , ... ... will help busy nursing professionals advance their careers. Beginning in the fall of 2017, ... Nursing (BSN) degree in as few as 16 months and for as little as ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 Global ... This report on the prostate cancer therapeutics market ... global market. Increasing prevalence of prostate cancer, launch ... in the development of new drugs & therapeutic ... cancer drug due to lesser side effects are ...
(Date:4/19/2017)... 19, 2017  New research provides evidence that an old ... to a study released today that will be presented at ... in Boston , April 22 to 28, ... of Parkinson,s disease, the oral drug levodopa has long been ... But as the disease progresses, the effects of the medication ...
(Date:4/18/2017)... April 18, 2017 Viverae ® , a ... the integration of IBM ® Watson Campaign Automation, ... targeted communications for a personalized experience. Through digital engagement, ... their health in real time. The enhanced experience drives ... to members, wherever they are in their journey to ...
Breaking Medicine Technology: